Rituximab for aggressive non-Hodgkin's lymphoma
National Institute for Clinical Excellence
Record ID 32003001119
English
Authors' objectives:
To provide guidance on the use of rituximab for aggressive non-Hodgkin's lymphoma.
Authors' recommendations:
Guidance:
1.1 Rituximab is recommended for use in combination with a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for the first-line treatment of people with CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV (see Section 2.3). Rituximab is not recommended for use when CHOP is contraindicated.
1.2 The clinical and cost effectiveness of rituximab in patients with localised disease (Stage I) has not been established. It is recommended that rituximab be used in these circumstances only as part of ongoing or new clinical studies.
1.3 A specialist in the treatment of lymphomas should supervise the use of rituximab in combination with CHOP for the treatment of diffuse large-B-cell lymphoma.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=86763
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antibodies, Monoclonal
- Lymphoma, Non-Hodgkin
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.